Effect of famotidine on pharmacokinetics of domperidone in healthy volunteers after a single oral administration

Abstract

Abstract: AIM: To study the effect of famotidine on the pharmacokinetics of domperidone.METHODS: A single oral dose of domperidone 10 mg was given to 10 healthy volunteers under the condition of untaking or taking famotidine in a randomized, cross-over study.Plasma domperidone concentration was determined by a validated LC/MS/MS method.Pharmacokinetic parameters were calculated by DAS software and compared by t tests.RESULTS: The concentration-time curve of domperidone with untaking or taking famotidine was conformed to a two-compartment model.Under untaking and taking famotidine conditions, the main pharmacokinetic parameters,t max , C_max and AUC_0-tn , were 0.63 ±0.36 and 1.50 ±0.97 h, 9.91 ±5.45 and 4.30 ±5.01 μg·L^-1 , 39.57±10.46 and 32.43 ±9.61 μg·h·L^-1 respectively.The absorption of domperidone was delayed, and the peak concentration and area under curve were reduced significantly when famotidine was taken.CONCLUSION: Famotidine had a significant effect on the pharmacokinetics of domperidone after a single oral dose in healthy volunteer.

Key words: domperidone, famotidine, pharmacokinetics, LC/MS/MS

CLC Number:

R969.1

LIANG Yan, TIAN Shuo-han, SUN Pei-hong, ZHAO Xia, ZHOU Ying, LIU Yu-wang, CUI Yi-min. Effect of famotidine on pharmacokinetics of domperidone in healthy volunteers after a single oral administration[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1160-1163.

References

1 Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS.Domperidone.A review of its pharmacological activity pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic[J].Drugs, 1982;24:360-400
2 Barone JA.Domperidone:A peripherally acting dopamine2 -receptor antagonist[J].Ann Pharmacother, 1999;33:429-40
3 俞兵, 许伟明.多潘立酮的药理和临床[J].天津药学,2000;12:18-9
4 谢鹏雁, 王化虹, 张忠兵, 袁耀宗, 赵洪川, 蓝宇.多潘立酮和法莫替丁缓解慢性浅表性胃炎症状的疗效观察[J].中国实用内科杂志, 2005;25:446-7
5 王韶明, 王选民, 母凯平, 朱淑娇.多潘立酮与法莫替丁治疗胃食管反流病的临床观察[J].吉林医学, 2003;24:53
6 马改萍, 吴忠辽, 宋争艳, 吴宝成.3 种功能性消化不良药物治疗方案的成本-疗效分析[J].中国药房, 2005;16:1395-6
7 岳相照.多潘立酮与雷尼替丁联用治疗功能性消化不良201 例临床观察[J].临床中老年保健, 2002;5:23
8 邓彪.吗丁啉、雷尼替丁联用治疗反流性食管炎疗效观察[J].基础医学与临床, 1995;S1:13-4
9 Guslandi M, Dell'Oca M, Moltani V.Famotidine versus domperidone versus a combination of both in the treatment of reflux esophagitis[J].Gastroenterology , 1989;96:A191
10 Masci E, Testoni PA, Passaretti S, Guslandi M, Tittobello A.Comparison of ranitidine, domperidone maleate and ranitidine +domperidone maleate in the short-term treatment of reflux oesophagitis[J].Drugs ExPClin Res, 1985;11:687-92
11 Kulkarni PN, Batra YK,Wig j.Effects of different combinations of H2 receptor antagonist with gastrokinetic drugs on gastric fluid PH and volume in children-a comparative study[J].Int J Clini Pharmaco Ther, 1997;35:561-4
12 张黎明, 袁成, 冯琳, 朱丽青.多潘立酮对扑热息痛人体药代动力学的影响[J].中国医院药学杂志, 1992;12:486-8
13 Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Deata Z.Characterization of human cytochrome p450 enzymes catalyzing domperidone N-dealky lation and hydroxylation in vitro[J].Br J Clin Pharmacol, 2004;58:277-87
14 Tsujikawa K, Dan Y, Nogawa K, Sato H, Yamada Y, Murakami H, et al.Potentiation of domperidone-induced catalepsy by a Pglycoprotein inhibitor, cyclosporin A[J].Biopharm Drug Dispos,2003;24:105-14
15 郭建强, 谷成明.多潘立酮的作用机制及临床应用新进展[J].中华消化杂志, 2001;21:39-42
16 周孟群.消化系统药物的配伍及临床意义[J].成都医药,2000;26:60-1
17 Escolona F, Castano J, Pares N, Bisbe E, Monterde J.Comparison of effects of famotidine and ranitidine on gastric secretion in patients undergoing elective surgery[J].Anaesthesia, 1989;44:212-5
18 方向明.消化性溃疡[ A].见:于皆平, 王小众, 张介眉, 主编.胃部疾病的诊断和治疗[M].第1 版.北京:人民卫生出版社, 2004:354-87
19 郭敏, 吴发明, 柯红.大剂量吗叮啉治疗胃食管反流病的疗效观察[J].湖北民族学院学报(医学版) , 2003;20:23-4

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[6]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[9]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[12]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[13]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[14]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[15]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.